Eli Lilly hikes sales outlook, as CEO says there's room for 'dramatic' obesity market expansion
Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.
This is a summary aggregated from CNBC. Read the complete article on the original site:
Read full article at CNBC
